ImmunoVec — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

ImmunoVec is a private, pre-clinical stage biotech pioneering a platform for precise in vivo cell engineering. The company's technology centers on proprietary synthetic promoters and expression cassettes that enable cell type-specific transcriptional control of DNA-encoded payloads, aiming to overcome the challenge of off-target effects in gene therapy. This platform-agnostic approach is being applied to develop therapies across viral (e.g., AAV, Lentivirus) and non-viral (e.g., LNP, exosome) delivery systems. As a young company, ImmunoVec is likely focused on platform validation, pipeline development, and securing venture funding to advance its programs toward the clinic.

RNA & Gene Therapy

Technology Platform

Proprietary platform for designing cell type and cell state-specific synthetic promoters and expression cassettes that enable precise transcriptional control of DNA-encoded payloads. The technology is delivery-agnostic, compatible with both viral (AAV, Lentivirus) and non-viral (LNP, exosome) vectors.

Opportunities

The platform addresses a core limitation in gene therapy—off-target expression—potentially improving the safety and efficacy of treatments across oncology, genetic diseases, and regenerative medicine.

Its delivery-agnostic nature allows it to leverage advancements across the entire vector landscape.

Successful validation could lead to high-value partnerships or acquisition by larger biopharma companies seeking targeting solutions.

Risk Factors

The core technology of achieving absolute cell-type specific expression in vivo is unproven and faces significant biological complexity.

As an early-stage platform company, it faces intense competition, intellectual property challenges, and high burn rate with total dependence on venture capital financing.

Managing R&D across multiple delivery modalities may stretch limited resources.

Competitive Landscape

ImmunoVec operates in a competitive space with companies developing cell-specific promoters (e.g., LogicBio, Synthetic Genomics), targeted AAV capsids, and tissue-specific LNPs. It also competes with broader gene editing and therapy platforms (e.g., CRISPR Therapeutics, Beam Therapeutics) that are investing in delivery and control systems. Differentiation hinges on the claimed precision and versatility of its transcriptional control elements.

More companies in Cell & Gene Therapy →More companies in United States →